

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 00-1312-C) PATENT

7-23 03

In re Application of: Kopreski)
Serial No.: 09/966,515) Before the Examiner:
, , , , , , , , , , , , , , , , , , ,)
Filed: September 28, 2002) Group Art Unit: 1655
For: Method Enabling Use of)
Extracellular RNA Extracted from)
Plasma or Serum to Detect, Monitor	
Or Evaluate Cancer)

TRANSMITTAL LETTER

Mail Stop Issue Fee Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

- 1. We are transmitting herewith the attached:
 - a) Issue Fee PTOL-85 transmittal
 - b) Statement Pursuant to 37 C.F.R. § 1.97(e)
 - c) 1449 Form and copy of cited reference
 - d) Interview summary
 - e) Return postcard
- 2. With respect to fees:
 - a) No fees are required
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
- 3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage Express Mail in an envelope addressed to the Mail Stop Issue Fee, Commissioner for Patents, Alexandria, VA 22313-1450 on July 22, 2003.

Respectfully submitted,

Date: July 22, 2003

Kevin E. Noonan Registration No. 35,303



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 00-1312-C)

PATENT
In application of:

Kopreski

Serial No. 09/966,515

Filed: September 28, 2001

For: Method Enabling the Use of Extracellular RNA Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer

PATENT

Before the Examiner:

F. Lu

Group Art Unit: 1634

Forum Method Enabling the Use of Extracellular Detect, Monitor or Evaluate Cancer

STATEMENT PURSUANT TO 37 C.F.R. §1.97(e)

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to the provisions of 37 C.F.R. §1.97(e), Applicants hereby state that the references cited in the accompanying Information Disclosure Statement were not known to anyone under the duty of disclosure set forth in 37 C.F.R. §1.56 more than three months prior to the date that this paper and the accompanying Information Disclosure Statement are submitted.

The U.S. Patent and Trademark Office is authorized to charge Deposit Account 13-2490 for the full amount of the fee required under 37 C.F.R. §1.17(p). Applicant is entitled to Small Entity Status.

Should the Examiner believe a discussion of this matter would be helpful, he is invited to telephone the undersigned at (312) 913-0001.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

By:

Kevin E. Noonan Reg. No. 35,303

Date: July 22, 2003

McDonnell Boehnen Hulbert & Berghoff 300 S. Wacker Drive Chicago, IL 60606 (312) 913-0001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 00-1312-C)

				PATENI
In app	licatio	on of:)	
)	
		Kopreski)	Before the Examiner:
		•)	F. Lu
Serial :	No.	09/966,515)	
		•)	Group Art Unit: 1634
Filed:		September 28, 2001)	
For:	Meth	od Enabling the Use of Extracellular)	
1		Extracted from Plasma or Serum to	Ś	
		t, Monitor or Evaluate Cancer)	
	Detec	i, Monitor of Evaluate Cancer)	

INTERVIEW SUMMARY

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to the provisions of MPEP §713.04, Applicants hereby provide a statement of the substance of the interview.

In a telephonic interview initiated by Examiner Lu, Applicant's undersigned representative and the Examiner discussed the Examiner's proposed amendments to the pending claims. Applicant's representative accepted the Examiner's proposed amendment, which were entered as Examiner's amendments as set forth in the "Reasons for Allowance" section accompanying the Notice of Allowability mailed April 22, 2003.

Should the Examiner believe a discussion of this matter would be helpful, he is invited to telephone the undersigned at (312) 913-0001.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

By:

Kevin E. Noonan Reg. No. 35,303

Date: July 22, 2003

McDonnell Boehnen Hulbert & Berghoff 300 S. Wacker Drive Chicago, IL 60606 (312) 913-0001

	Application No.	Applicant(s)				
Interview Summary	09/966,515	KOPRESKI, MICHAEL S.				
	Examiner	Art Unit				
	Frank W Lu	1634				
All participants (applicant, applicant's representative, PTO personnel):						
(1) <u>Frank W Lu</u> .	(3)					
(2) Mr.Kevin Noonan (Reg. No. 35,303).	(4)					
Date of Interview: 16 April 2003	•					
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant 2)□ applicant's representative]						
∴xhibit shown or demonstration conducted: d) Yes e) No. If Yes, brief description: Applicant agreed with the examiner's amendments.						
Claim(s) discussed: <u>1-53</u> .		,				
Identification of prior art discussed:						
Agreement with respect to the claims f)⊠ was reached. g)□ was not reached. h)□ N/A.						
Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: <u>Mr. Noonan agreed with the examiner's amendments (see the examiner's amendments).</u>						
(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)						
THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.						
	•					
·.						
	· · · · · · · · · · · · · · · · · · ·	,				
	Tul	(ii/				
Examiner Note: You must sign this form unless it is an Attachment to a signed Office action	Examiner's sign	nature if required				